TargetMol

Topotecan hydrochloride

Product Code:
 
TAR-T1174
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T1174-5mg5mg£95.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1174-10mg10mg£108.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1174-1mL1 mL * 10 mM (in DMSO)£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1174-25mg25mg£129.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1174-50mg50mg£158.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1174-100mg100mg£189.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1174-500mg500mg£362.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Topotecan hydrochloride is an antineoplastic agent used to treat ovarian cancer.
CAS:
119413-54-6
Formula:
C23H24ClN3O5
Molecular Weight:
457.91
Pathway:
Autophagy; DNA Damage/DNA Repair; Apoptosis
Purity:
0.9876
SMILES:
Cl.CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O
Target:
Apoptosis; Topoisomerase; Autophagy

References

1. Caceres G, et al. Anticancer Drugs. 2003, 14(7), 569-574. 2. Uckun FM, et al. Blood. 1995. 85(10), 2817-2828. 3. Ciusani E, et al. J Neurooncol. 2005, 71(1), 19-25. 4. McCluskey AG, et al. J Nucl Med. 2012, 53(7), 1146-1154. 5. Romanelli S, et al. Cancer Chemother Pharmacol. 1998, 41(5), 385-390.